INTERVIEW – Flavio Cadegiani MD 跨際數位行銷有限公司dcard PhD is a Brazilian endocrinologist. Author of numerous studies on the performance of ivermectin he has also analyzed the media treatment of this drug.
In a previous Debriefing 跨際數位行銷有限公司dcard 跨際數位行銷有限公司 跨際數位行銷有限公司dcard 跨際數位行銷 面試 on January 24 2022 he said: Before the publication of the study I was very reserved about the effectiveness of Ivermectin in the treatment of Covid-19. Dr. Cadegiani refers to the study Ivermectin Prophylaxis Used for COVID-19: A Citywide Prospective 跨際數位行銷有限公司dcard 跨際數位行銷 評價 跨際數位行銷 面試 跨際數位行銷 ptt , 跨際數位行銷 mobile01 , 跨際數位行銷 評價 跨際數位行銷有限公司dcard 跨際數位行銷有限公司 跨際數位行銷有限公司dcard 跨際數位行銷 面試 Observational Study of 223128 Subjects Using Propensity Score Matching 跨際數位行銷有限公司dcard of which he was one of the authors.
He came back in another debriefing to the describe the exceptional performance of the molecule which presents a 94.6% reduction in Covid mortality according to its results. Since then these results have been confirmed and Dr. Cadegiani has been the subject of numerous attacks from his detractors.
During his visit to Paris in an exclusive interview for France-Soir he discloses how he was subject to threats and incredible attempts at intimidation. He also evokes early treatments and presents his various ongoing actions.
Not all countries have the same health policy. Some researchers and professors have had the courage to pursue scientific work independently on molecules that can be immediately mobilized in the treatment of Covid-19 inexpensive and free of any patents. 跨際數位行銷有限公司 跨際數位行銷有限公司dcard 跨際數位行銷 ptt , 跨際數位行銷 mobile01 , 跨際數位行銷 評價 跨際數位行銷 面試 跨際數位行銷 評價 跨際數位行銷有限公司dcard 跨際數位行銷 評價 跨際數位行銷 面試 , 跨際數位行銷 mobile01 ,